Back
Return
Biography
Pere Domingo

Dr. Pere Domingo

Autonomous Unversity of Barcelona, Spain

 

Email: pdomingo@santpau.cat

 

Qualifications

1992  Ph.D., Universitat Autònoma de Barcelona, Spain

1979  M.D., Universidad de Barcelona, Spain

1973  B.S., Universidad de Barcelona, Spain

 

Publications (Selected)

  1. Podzamczer D, Miró JM, Bolao F, Cosín J, Sirera G, Domingo P, Laguna F, Santamaría J, Verdejo J, and the Spanish Toxoplasmosis Study Group. Twice-weekly versus daily maintenance therapy with sulfadiazine-pyrimethamine for toxoplasmic encephalitis in AIDS patients. Ann Intern Med 1995; 123: 175-180.
  2. López-Navidad A, Domingo P, Caballero F, González C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation 1997; 64: 365-368.
  3. Barquet N, Domingo P, Caylà JA, González J, Rodrigo C, Fernández-Viladrich P, Moraga-Llop FA, Marco F, Vázquez J, Sáez-Nieto JA, Casal J, Canela J, Foz M,for the Barcelona Meningococcal Disease Study  Group. Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system.  JAMA 1997; 278: 491-496.
  4. Domingo P, Barquet N, Alvarez M, Coll P, Nava J, Garau J. Group B streptococcal meningitis in adults. Report of twelve cases and review. Clin Infect Dis 1997; 25: 1180-1187.
  5. Domingo P, Fontanet A, Sánchez F, Allende L, Vazquez G. Morbidity associated with long-term use of totally implantable ports in patients with AIDS. Clin Infect Dis 1999; 29: 346-351.
  6. Barquet N, Domingo P, Caylà JA, González J, Rodrigo C, Fernández-Viladrich P, Moraga-Llop FA, Marco F, Vázquez J, Sáez-Nieto JA, Casal J, Canela J, Foz M, and the Barcelona Meningococcal Disease Study Group. Meningococcal disease in a large urban population: predictors of dismal prognosis. Arch Intern Med 1999; 159: 2329-2340.
  7. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Sambeat MA, Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1-protease inhibitor-associated lipodystrophy. AIDS 1999; 13: 2261-2267.
  8. López JC, Miró JM, Peña JM, Podzamczer D, Alberdi JC, Claramonte X, Cosín J, Martínez E, Gonzalez J, Domingo P, et al. Discontinuation of primary and secondary Pneumocystis carinii prophylaxis is safe in HIV-infected patients after immunological restoration with HAART. Results of an open, randomized and multicentric clinical trial (GESIDA 04/98). N Engl J Med 2001; 344: 159-167.
  9. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease following initiation of highly active antiretroviral therapy in HIV-1 infected patients. Am J Med 2001; 110: 605-609.
  10. Domingo P, Matias-Guiu X, Pujol RM, Domingo JC, Arroyo JA, Sambeat MA, Vazquez G. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis. J Infect Dis 2001; 184: 1197-1201.
  11. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force Ll, Segura F, Richart C, Cortes  C, Javaloyas M, Aranda M, Gatell JM. Switching from protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label simplification trial in successfully treated HIV-1-infected patients. N Engl J Med 2003; 349: 1036-1046.
  12. Martínez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B, and the SWATCH Study Team. Alternation of antiretroviral drug regimens for HIV infection: a randomized trial. Ann Intern Med 2003;139: 81-89.
  13. Domingo P, Labarga P, Palacios R, Fernández-Guerrero M, Terrón JA, Pérez-Elias MJ, et al. Dyslipidaemia improvement in patients switching from stavudine to tenofovir: preliminary results from the Recover Study. AIDS 2004; 18: 1475-1478.
  14. Domingo P, Vidal F, Domingo JC, Veloso S, Sambeat MA, Torres F, Sirvent J, Vendrell J, Matias-Guiu X, Richart C. Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy: its role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005 ; 35 : 771-780.
  15. Giralt M, Domingo P, Guallar JP, Rodriguez ML, Alegre M, Domingo JC, Villarroya  F. Human immunodeficiency virus type 1 (HIV-1) infection alters gene expression in adipose tissue, contributing to HIV/highly active antiretroviral therapy-associated lipodystrophy. Antivir Ther 2006; 11: 729-740.
  16. Moreno-Torres A, Domingo P, Pujol R, Blanco F, Arroyo JA, Sambeat MA. Liver fat content in HIV-1-infected patients on combination antiretroviral therapy: correlation with metabolic alterations. Antivir Ther 2007; 12: 195-203.
  17. Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, García Alcalde ML, Cosín J, Terrón A,  Galindo MJ,Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA Study, a non-randomized comparison from the VACH Cohort. J Antimicrob Chemother 2008; 61: 1348-1358.
  18. Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M, the VACH Cohort Study Group. Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51: 582-587.
  19. Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez MM, Mateo MG, Domingo JC, Fernandez I, Villarroya F, Muñoz J, Vidal F, Baiget M. Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine triphosphate intracellular levels in patients with stavudine-based antiretroviral regimes. Clin Infect Dis 2010; 50: 1033-1040.
  20. Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez MM, Mateo MG, Fernandez I, Vidal F, Giralt M, Villarroya F. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010; 24: 2629-2637.
  21. Domingo P, Torres-Torronteras J, Pomar V, Giralt M, Domingo JC, Gutierrez MM, Gallego-Escuredo JM, Mateo MG, Cano-Soldado P, Fernandez I, Pastor-Anglada M, Vidal F, Villarroya F, Andreu A, Marti R. Uridine metabolism in HIV-1-infected patients: the role of infection, highly active antiretroviral therapy (HAART) and the development of HIV-1/HAART-associated lipodystrophy syndrome (HALS). PLOs One 2010; 5: e13896.
  22. Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez MM, Paré L, Mateo MG, Muñoz J, Domingo JC, Fernández I, Villarroya F, Vidal F, Baiget M. Association of thymidylate synthase polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother 2011; 55: 1428-143.